ABEONA THERAPEUTICS INC. (ABEO) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-07

Key Insights

Abeona Therapeutics has expanded its Board of Directors from nine to ten members, appointing Keith A. Goldan as a new independent director and Chair of the Audit Committee.
Goldan's appointment and the associated $150,000 one-time equity grant suggest the company is strengthening its leadership and governance.
The press release announcing Goldan's appointment indicates the company is proactively communicating this change to investors.

Want the newest filings?

This analysis covers the filing from 2026-04-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-20

Abeona Therapeutics has amended its bylaws to provide more clarity around calling and conducting stockholder meetings, including allowing for virtual meetings.
The company has increased the quorum requirement for stockholder meetings from one-third to 50%, indicating a focus on ensuring robust stockholder participation.
The amendments enhance the disclosure and procedural requirements for stockholder proposals and director nominations, potentially increasing transparency.

Other reports for ABEONA THERAPEUTICS INC.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.